Preliminary evaluation of immune checkpoint inhibitors as a salvage treatment of tumor recurrence after liver transplantation for hepatocellular carcinoma
10.3760/cma.j.cn421203-20220420-00081
- VernacularTitle:6例免疫检查点抑制剂挽救性治疗肝癌肝移植术后肿瘤复发的初步评价
- Author:
Jingqi SUN
1
;
Zhe YANG
;
Jianpeng LIU
;
Qijian YU
;
Zhaoxin SHANG
;
Shuo WANG
;
Li ZHUANG
;
Xiao XU
;
Shusen ZHENG
Author Information
1. 浙江大学医学院附属第一医院肝胆胰外科，杭州 310003
- Keywords:
Liver transplantation;
Hepatocellular carcinoma;
Immune checkpoint inhibitors;
Recurrence
- From:
Chinese Journal of Organ Transplantation
2022;43(7):396-399
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the safety and efficacy of immune checkpoint inhibitors(ICI)for patients with tumor recurrence after liver transplantation(LT).Methods:A single-center retrospective study was conducted for 6 recipients of tumor recurrence after LT on a therapy of ICI admitted into Shulan(Hang Zhou)Hospital from September 2015 to June 2018.The authors examined the occurrences of graft rejection and clinical outcomes of overall response rate, progression-free survival and overall survival after dosing of PD-1/PD-L1 inhibitors.Results:Six patients enrolled with tumor recurrence on a therapy of ICI undergoing LT due to hepatocellular carcinoma (HCC). Nivolumab (n=4) and duvalizumab (n=2) were administrated.The median session of treatment was 8.3(2-31) cycles.The disease outcomes were stable (3/6, 50%) and progressive (3/6, 50%), The progression-free survival time of 3 disease-controlled patients was 1.5, 16.2 and 18 months and the median survival time after recurrence was 19.75(10.8-37.8) months.Rejection occurred in 1 patients (1/6, 16.7%) and the occurring time of rejection was 28 days after PD-1 inhibitor dosing.After acute rejection, high-dose corticosteroids and immunoglobulin were ineffective and the patient died from acute rejection related liver failure.Conclusions:ICI may be employed as a salvage treatment for tumor recurrence after LT for HCC.Due to a possibility of severe acute rejection, usage should be cautious under close monitoring of liver function.
